Biocon FY26 Revenue ₹17,270 Cr, Profit ₹436 Cr; Recommends ₹0.50 Dividend
Biocon reported Q4FY26 total income of ₹4,569 Cr and FY26 total income of ₹17,270 Cr. FY26 net profit before exceptional items was ₹436 Cr, a 323% YoY increase. The company recommended a final dividend of ₹0.50 per share. Biosimilars revenue grew 16% YoY to ₹10,431 Cr in FY26.
The announcement includes full-year financial results, profit growth, and dividend declaration, which are material information for investors and significantly impact the company's valuation.
The company reported significant year-on-year growth in revenue and profit, along with a recommended dividend, indicating strong financial performance.
Biocon Limited announced its consolidated financial results for the fiscal fourth quarter and the financial year ended March 31, 2026. For Q4FY26, Total Income was ₹4,569 Crore, up 10% YoY, with Operating Revenue at ₹4,517 Crore, also up 10% YoY (excluding one-time generic lenalidomide sales in Q4FY25). EBITDA stood at ₹1,073 Crore, a 29% YoY increase, with an EBITDA margin of 23%. Net Profit before exceptional items was ₹179 Crore, a 64% YoY increase. For the full fiscal year FY26, Total Income reached ₹17,270 Crore, up 14% YoY, and Operating Revenue was ₹16,927 Crore, up 13% YoY (adjusted for one-time generic lenalidomide sales and BFI divestment gain). EBITDA for FY26 was ₹3,798 Crore, up 25% YoY, with an EBITDA margin of 22%. Net Profit before exceptional items surged by 323% YoY to ₹436 Crore. The Board of Directors has recommended a final dividend of ₹0.50 per share for FY26. In terms of business segments, Biosimilars revenue for FY26 was ₹10,431 Crore (up 16% YoY) and EBITDA was ₹2,751 Crore (up 40% YoY). Generics revenue for FY26 was ₹3,168 Crore (up 17% YoY), and Syngene's revenue for FY26 was ₹3,739 Crore (up 3% YoY). The company also announced the recommended appointment of several Independent Directors and a Non-Executive, Non-Independent Director, effective August 1, 2026. Shreehas Tambe has taken charge as CEO & Managing Director and Kedar Upadhye as Chief Financial Officer from April 1, 2026. Biocon was recognized for its sustainability efforts and included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.